References
- 1. J. K. Liao and U. Laufs, Pleiotropic effects of statins, Annu. Rev. Pharmacol. Toxicol. 45 (2005) 89-118; DOI: 10.1146/annurev.pharmtox.45.120403.095748.
- 2. S. Wolfrum, K. S. Jensen and J. K. Liao, Endothelium-dependent effects of statins, Arterioscler. Thromb. Vasc. Biol. 23 (2003) 729-736; DOI: 10.1161/01.ATV.0000063385.12476.A7.
- 3. L. Taraseviciene-Stewart, R. Scerbavicius, K. H. Choe, C. Cool, K. Wood, R. M. Tuder, N. Burns, M. Kasper and N. F. Voelkel, Simvastatin causes endothelial cell apoptosis and attenuates severe pulmonary hypertension, Am. J. Physiol. Lung Cell Mol. Physiol. 291 (2006) L668-L676; DOI: 10.1152/ ajplung.00491.2005.
- 4. R. E. Girgis, D. Li, X. Zhan, J. G. Garcia, R. M. Tuder, P. M. Hassoun and R. A. Johns, Attenuation of chronic hypoxic pulmonary hypertension by simvastatin, Am. J. Physiol. Heart Circ. Physiol. 285 (2003) H938-945; DOI: 10.1152/ajpheart.01097.2002.
- 5. F. Simko, Statins: a perspective for left ventricular hypertrophy treatment, Eur. J. Clin. Invest. 37 (2007) 681-691; DOI: 10.1111/j.1365-2362.2007.01837.x.
- 6. P. J. Delahoy, D. J. Magliano, K. Webb, M. Grobler and D. Liew, The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes: an updated meta-analysis, Clin. Ther. 31 (2009) 236-244; DOI: 10.1016/j.clinthera.2009.02.017.
- 7. M. Satoh and A. Satoh, 3-Hydroxy-3-methylglutaryl (HMG)-COA reductase inhibitors and phosphodiesterase type V inhibitors attenuate right ventricular pressure and remodeling in a rat model of pulmonary hypertension, J. Pharm. Pharm. Sci. 11 (2009) 118s-130s.
- 8. X. Sun and D. D. Ku, Rosuvastatin provides pleiotropic protection against pulmonary hypertension, right ventricular hypertrophy, and coronary endothelial dysfunction in rats, Am. J. Physiol. Heart Circ. Physiol. 294 (2008) H801-H809; DOI: 10.1152/ajpheart.01112.2007.
- 9. Y. Pei, P. Ma, X. Wang, W. Zhang, X. Zhang, P. Zheng, L. Yan, Q. Xu and G. Dai, Rosuvastatin attenuates monocrotaline-induced pulmonary hypertension via regulation of Akt/eNOS signaling and asymmetric dimethylarginine metabolism, Eur. J. Pharmacol. 666 (2011) 165-172; DOI: 10.1016/j. ejphar.2011.05.035.
- 10. V. G. DeMarco, J. Habibi, A. T. Whaley-Connell, R. I. Schneider, J. R. Sowers, B. T. Andresen, A. A. Gutweiler, L. Ma, M. S. Johnson, C. M. Ferrario and K. C. Dellsperger, Rosuvastatin ameliorates the development of pulmonary arterial hypertension in the transgenic (mRen2)27 rat, Am. J. Physiol. Heart Circ. Physiol. 297 (2009) H1128-1139; DOI: 10.1152/ajpheart.00048.2009.
- 11. T. Kuang, J. Wang, B. Pang, X. Huang, E. D. Burg, J. X. Yuan and C. Wang, Combination of sildenafil and simvastatin ameliorates monocrotaline-induced pulmonary hypertension in rats, Pulm. Pharmacol. Ther. 23 (2010) 456-464; DOI: 10.1016/j.pupt.2010.02.003.
- 12. L. Zhao, A. Sebkhi, O. Ali, B. Wojciak-Stothard, L. Mamanova, Q. Yang, J. Wharton and M. R. Wilkins, Simvastatin and sildenafil combine to attenuate pulmonary hypertension, Eur. Respir. J. 34 (2009) 948-957; DOI: 10.1183/09031936.00143508.
- 13. D. S. Lee, Y. K. Kim and Y. W. Jung, Simvastatin, sildenafil and their combination in monocrotaline induced pulmonary arterial hypertension, Korean Circ. J. 40 (2010) 659-664; DOI: 10.4070/ kcj.2010.40.12.659.
- 14. X. L. Li, R. J. Guan, Q. H. Xu and Z. Y. Wu, [Effects of rosuvastatin on monocrotaline-induced pulmonary artery hypertension in rats], Zhonghua Xin Xue Guan Bing Za Zhi. 39 (2011) 247-253.
- 15. R. T. Schermuly, K. P. Kreisselmeier, H. A. Ghofrani, A. Samidurai, S. Pullamsetti, N. Weissmann, C. Schudt, L. Ermert, W. Seeger and F. Grimminger, Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension, Circ. Res. 94 (2004) 1101-1108; DOI: 10.1161/01.RES.0000126050.41296.8E.
- 16. M. Jasińska-Stroschein, J. Owczarek, A. Łuczak, and D. Orszulak-Michalak, The beneficial impact of fasudil and sildenafil on monocrotaline-induced pulmonary hypertension in rats: A hemodynamic and biochemical study, Pharmacology 91 (2013) 178-184; DOI: 10.1159/000346921.
- 17. N. Galiè, M. M. Hoeper, M. Humbert, A. Torbicki, J. L. Vachiery, J. A. Barbera, M. Beghetti, P. Corris, S. Gaine, J. S. Gibbs, M. A. Gomez-Sanchez, G. Jondeau, W. Klepetko, C. Opitz, A. Peacock, L. Rubin, M. Zellweger and G. Simonneau, ESC Committee for Practice Guidelines (CPG): Guidelines for the diagnosis and treatment of pulmonary hypertension: the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT), Eur. Heart. J. 30 (2009) 2493-2537; DOI: 10.1093/eurheartj/ehp297.
- 18. M. R. Wilkins, O. Ali, W. Bradlow, J. Wharton, A. Taegtmeyer, C. J. Rhodes, H. A. Ghofrani, L. Howard, P. Nihoyannopoulos, R. H. Mohiaddin and J. S. Gibbs, Simvastatin Pulmonary Hypertension Trial (SiPHT) Study Group, Simvastatin as a treatment for pulmonary hypertension trial, Am. J. Respir. Crit. Care Med. 181 (2010) 1106-1113; DOI: 10.1164/rccm.2009111-699OC.
- 19. C. Transon, T. Leemann and P. Dayer, In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors, Eur. J. Clin Pharmacol. 50 (1996) 209-215.
- 20. W. J. Zeng, C. M. Xiong, L. Zhao, G. L. Shan, Z. H. Liu, F. Xue Q. Gu, X. H. Ni, Z. H. Zhao, X. S. Cheng, M. R. Wilkins and J. G. He, Atorvastatin in pulmonary arterial hypertension (APATH) study, Eur. Respir. J. 40 (2012) 67-74; DOI: 10.1183/09031936.00149011.
- 21. E. Abulhul, K. McDonald, R. Martos, D. Phelan, J. P. Spiers, M. Hennessy, J. Baugh, C. Watson, C. O’Loughlin and M. Ledwidge, Long-term statin therapy in patients with systolic heart failure and normal cholesterol: effects on elevated serum markers of collagen turnover, inflammation, and B-type natriuretic peptide, Clin. Ther. 34 (2012) 91-100; DOI: 10.1016/j.clinthera.2011.11.002.
- 22. Y. Teshima, K. Yufu, H. Akioka, T. Iwao, F. Anan, M. Nakagawa, H. Yonemochi, N. Takahashi, M. Hara and T. Saikawa, Early atorvastatin therapy improves cardiac function in patients with acute myocardial infarction, J. Cardiol. 53 (2009) 58-64; DOI: 10.1016/j.jjcc.2008.08.008.
- 23. D. Chen, D. Zhou, J. Qian, F. Chen, L. Guan, L. Dong and J. Ge, Atorvastatin prevents dehydromonocrotaline- induced pulmonary hypertension in beagles, Exp Lung Res. 38 (2012) 333-343; DOI: 10.3109/01902148.2012.702852.
- 24. S. Yigitaslan and B. Sirmagul, Relation of bosentan, iloprost, and sildenafil with growth factor levels in monocrotaline-induced pulmonary hypertension, Clin. Exp. Hypertens. 34 (2012) 222-229; DOI: 10.3109/10641963.2011.631652.
- 25. K. T. Mouchaers, I. Schalij, M. A. de Boer, P. E. Postmus, V. W. van Hinsbergh, G. P. van Nieuw Amerongen, A. Vonk Noordegraaf and W. J. van der Laarse, Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil, Eur. Respir. J. 36 (2010) 800-807; DOI: 10.1183/09031936.00130209.